A utoimmune polyendocrine syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (OMIM 240300), is a rare autosomal recessive disorder caused by mutations in the autoimmune regulator (AIRE) gene encoded on chromosome 21q22.3 (1, 2) . The autoimmune regulator is an important mediator of central tolerance by promoting the expression of organ-specific antigens in the thymus (3) (4) (5) .
The classical triad of APS1 include hypoparathyroidism, adrenal failure and chronic mucocutaneous candidiasis (6) . In addition, other organ-specific autoimmune diseases such as gonadal failure, intestinal dysfunction, type 1 diabetes mellitus, hypothyroidism and pituitary insufficiency as well as ectodermal manifestations are found with variable penetrance.
High titer autoantibodies (Aabs) against intracellular key enzymes, primarily involved in the synthesis of steroids or neurotransmittors, is a hallmark of APS1 (7) (8) (9) (10) . These Aabs constitute important diagnostic markers and are sometimes predictive of disease manifestations (11, 12) . Hypopituitarism is a rare manifestation of APS1. Isolated growth hormone (GH)-deficiency has to the best of our knowledge only been reported in 10 APS1 patients (6, (13) (14) (15) (16) (17) , isolated hypogonadotroph hypogonadism in one patient (13) and central diabetes insipidus in three (18) (19) (20) . Three siblings with APS1 and partial adrenocorticotropic hormone deficiency have been described (21) . One APS1 patient with multiple pituitary hormonal insufficiencies has also been reported (22) .
Pituitary Aabs against prolactin secreting cells have been detected by conventional immunofluorescence in sera from a few APS1 patients (6, 23) . Immunoreactivity against median eminence dopaminergic nerve terminals and pituitary gonadotrops have been shown in an APS1 patient with GH deficiency (24) . By using an immunoblotting method with pituitary homogenate, Aabs to a 49-kDa antigen was detected in 39/67 (58%) APS1 patients (25) . The 49-kDa pituitary protein has been identified as ␣-enolase (26) , but the importance of enolase Aabs as markers for neuroendocrine autoimmunity has been debated (27) . Moreover, no correlations between pituitary Aabs and pituitary dysfunction in APS1 have been described.
In this study, we aimed to identify novel pituitary autoantigens in patients with APS1 by immunohistochemistry and immunoscreening of a human pituitary cDNA expression library.
Results

Identification of Tudor Domain Containing Protein 6 (TDRD6) as an
Autoantigen.
A pituitary cDNA expression library was constructed and screened with sera from two APS1 patients. Twenty-seven cDNA clones were isolated and partially sequenced. Four of the clones encoded tryptophan hydroxylase (TPH) isoform 1, a well known APS1 autoantigen (9) . In vitro transcription and translation (ITT) of other cDNA clones resulted in 10 recombinant proteins that were used for immunoprecipitation with a test panel of sera from six APS1 patients and five healthy blood donors. Most of these recombinant products were recognized solely by the screening serum, by both APS1 sera and control sera or by none of the sera. A protein encoded by a tudor domain containing protein 6 (TDRD6) cDNA clone was, however, efficiently immunoprecipitated by two of the The authors declare no conflict of interest.
Abbreviations: Aab, autoantibody; AADC, aromatic-L-amino acid decarboxylase; APS1, autoimmune polyendocrine syndrome type 1; GAD, glutamic acid decarboxylase; GH, growth hormone; ITT, in vitro transcription and translation; TDRD6, tudor domain containing protein 6; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase.
Data deposition: The TDRD6 mRNA reference sequence reported in this paper has been deposited in the GenBank database (accession no. EF 185284).
APS1 sera but not by any of the healthy blood donor sera and was therefore selected for further studies.
The TDRD6 gene which is located on chromosome 6p12.3 consists of four exons and spans over a region of 14 kb. The TDRD6 mRNA reference sequence reported in GenBank (accession no NM001010870.1) is 6.8 kb long and encodes a 2,096-aa protein. Several different TDRD6 cDNA sequences with different putative transcriptional start sites and alternative splicing have been reported. The TDRD6 cDNA clone identified in this study spans from the middle of exon 1 to intron 3 and retains intron 1. Because of a termination codon, 6 bp into intron 1, the protein is truncated, and this cDNA is predicted to encode a 925-aa protein. Details on TDRD6 cDNA clones are in supporting information (SI) Fig. 5 .
Immunoprecipitation of in Vitro Translated TDRD6 Fragment with
Patient Sera. To determine whether immunoreactivity against TDRD6 was APS1 related, sera obtained from 86 APS1 patients, 93 patients with other autoimmune diseases and 90 healthy blood donors were tested for immunoreactivity against TDRD6. Forty-two of the 86 (49%) APS1 patients showed positive immunoreactivity against the in vitro translated TDRD6 fragment. No TDRD6 Aabs were found in sera from patients with isolated lymphocytic hypophysitis, Addison's disease, type 1 diabetes mellitus, Sjögren's syndrome, systemic lupus erythematosus, or healthy blood donors (Fig. 1) . We found no associations between immunoreactivity against TDRD6 and clinical manifestations of APS1 (Table 1) . Two of six APS1 patients with GH-deficiency showed positive immunoreactivity against TDRD6, but the limited number did not allow statistical interpretation.
Immunohistochemical Findings. Three of the six (50%) APS1 patients with GH-deficiency ( Table 2 , patients 1, 3, and 6) showed immunoreactivity against a small cell population in the guinea pig anterior pituitary lobe. We selected the patient serum that showed the strongest immunoreactivity ( Table 2 , patient 3) and performed double-staining for the following pituitary hormones: follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, prolactin, adrenocorticotropic hormone or GH. No coexistence was found ( Fig. 2 A-E), the GH antiserum being an exception (Fig. 2 F and G) . Thus, 40-50% of the APS1-positive cells were GH-positive with serum no. 3. Conversely, Ͻ1% of the GH cells stained with the APS1 serum. Subsequently, about the same percentage were observed for patients 1 and 6. The APS1 immunofluorescence pattern showed aggregates of staining, distinctly different from the small, singular granules containing GH, suggesting that the targeted autoantigen(s) is not colocalized or cosecreted with GH (Fig.  2G) . None of the ten sera from healthy control subjects showed any staining.
The APS1 sera were preadsorbed with TDRD6 or enzymes (glutamic acid decarboxylase, GAD; aromatic-L-amino acid decarboxylase, AADC; tyrosine hydroxylase, TH; or TPH). Preadsorption with AADC, but with none of the other proteins, abolished the staining in one of three APS1 patients ( Table 2 , patient 1) (compare Fig. 3 B with A) .
In the rat intermediate lobe, four APS1 sera (patients 1, 3, 5, and 6, Table 2 ) showed a distinctly stained fiber plexus (Fig. 4A) . Adsorption of one APS1 serum ( Table 2 , patient 5) with GAD alone caused a strong reduction in the number of fluorescent terminals (compare Fig. 4 B with A) , whereas the effect of AADC or TH was less pronounced (compare Fig. 4 C and D with  A) and that of TPH negligible (compare Fig. 4 E with A) . No fluorescent structures were seen after incubation with a mix of all four enzymes (compare Fig. 4 F with A) . Table 2 shows presence of Aabs against GAD, AADC, TH, and TPH among the six APS1 patients with GH-deficiency as detected by immunoprecipitation. No sera from healthy controls showed immunoreactivity against any of the four enzymes.
Discussion
By immunoscreening of a human pituitary cDNA library, we have identified TDRD6 as a major autoantigen in APS1. TDRD6 is known to be mainly expressed in the testis and only at very low levels in other endocrine tissues like the pituitary, adrenal gland, and pancreas (http://expression.gnf.org) (28) . The function of TDRD6 is unexplored, but the protein is known to contain seven so-called tudor domains, that is, Ϸ60-aa repeats initially found in developmentally important proteins and first ascribed a putative RNA-binding function (29) . More recent studies have revealed, however, that tudor domains do not bind nucleic acids but instead proteins containing methylated arginines (30, 31) . No other protein motifs were detected.
In the present study, TDRD6 Aabs were frequently found among APS1 patients (42/86; 49%) by using an immunoprecipitation assay. These Aabs seem to be highly APS1 specific, because no immunoreactivity against in vivo translated TDRD6 was detected in a large number of sera from patients with organ-specific and systemic autoimmune diseases or healthy blood donors. TDRD6 has previously been identified as an autoantigen in a single patient with colon cancer (32); however apparently not cancer-related, because sera from 29 patients with colorectal cancer, in addition to 16 normal blood donors, tested negative for TDRD6 Aabs (32) .
We were unable to correlate TDRD6 immunoreactivity with any APS1 manifestation; perhaps not unexpected, because the number of APS1 patients with hypopituitarism is very small. Notably, the lowest P value was seen for correlation between TDRD6 Aabs and gonadal failure (P ϭ 0.168). This observation is interesting considering the TDRD6 expression pattern. The APS1 patients in the present report are all well characterized, but there is always a possibility of unrecognized manifestations, presence of subclinical disease or appearance of Aabs before the onset of clinical disease. To fully elucidate the possible correlations between gonadal failure and TDRD6 Aabs, more studies on TDRD6 immunoreactivity in patients with isolated and combined gonadal failure are needed. Also, it remains to be verified whether or not TDRD6 Aabs are related to other so far unrecognized APS1 manifestations.
Pituitary insufficiency is a rare manifestiation of APS1 and diagnosed in only 6 of our 86 patients. All these patients had an isolated GH-deficiency, but only two of which tested positive for TDRD6 Aabs, not allowing statistical interpretation.
The prevalence of TDRD6 immunoreactivity among APS1 patients (49%) is comparable with the high rates of Aabs against side-chain cleavage enzyme (52%), AADC (51%), and TPH (45%) (11) . However, TDRD6 is not structurally related to any of these APS1 autoantigens and sharing of antigen epitopes is not obvious.
In this study, Aabs against guinea pig anterior pituitary cells were detected in sera from 3/6 APS1 patients with GHdeficiency. Double-staining for pituitary hormones revealed a partial colocalization with GH-producing cells, somatotrophs. Recent publications suggest that Aabs against somatotrophs, when present in high titers, may be considered a good diagnostic marker for autoimmune forms of GH-deficiency (33, 34) .
To what extent presence of APS1 autoantigen, apparently only in a small number of GH cells and apparently not in the GH storage granules, may contribute to the GH-deficiency in these patients is unclear. It also remains to be established whether the APS1 autoantigen-positive cells seemingly not expressing any of the the classical anterior pituitary hormones represent a novel cell subpopulation.
Several of the major APS1 autoantigens are key enzymes in neurotransmitter synthesis, such as GAD, AADC, TH, and TPH which are all present in the pituitary, and one of our screening sera did identify clones encoding TPH. Because of this finding, we performed preadsorption tests with GAD, AADC, TH, and TPH. In one APS1 patient preadsorption with AADC abolished the staining, whereas preadsorption with the other enzymes or TDRD6 did not alter the immunostaining seen with patient sera. 
*Manifestation diagnosed after blood sampling for this study.
These results indicate the presence of further target autoantigen(s) than TDRD6 and AADC in anterior pituitary cells. The three sera also stained a nerve plexus in the intermediate pituitary lobe (compare ref. 24) , which is known to receive a dopaminergic (35, 36) and a GABAergic (37) innervation, both of central origin. These terminals are at least in part identical, in agreement with coexistence of TH and GAD in arcuate neurons (38) . In addition, there is a central serotonergic innervation of the intermediate lobe (39) which should contain TPH. Serotonin can also be present in dopamine terminals, but in this case after uptake by the dopamine transporter (40) , that is these terminals do not contain TPH. Taken together, in the intermediate lobe, there are presumably nerve terminals containing TH plus AADC (dopamine), TH plus AADC plus GAD (mixed dopamine-GABA), GAD alone, and TPH alone. The preadsorption results seem to reflect that distribution, GAD enzyme being most efficient in reducing staining.
In conclusion, TDRD6 is a major autoantigen in APS1 patients, and 3/6 sera from GH-deficient patients stain specific cell populations and nerves in the guinea pig pituitary gland.
It may be speculated that presence of APS1 autoantigen in GH cells may contribute to the GH-deficiency. Alternatively, autoantibodies directed against the transmitter-synthesizing enzymes, acting at the level of the median eminence/arcuate nucleus, could alter brain control of the pituitary, contributing to this disorder.
Materials and Methods
Patients. Serum samples from 86 APS1 patients, 42 men and 44 women, of Swedish (n ϭ 10), Norwegian (n ϭ 17), and Finnish (n ϭ 59) origin were analyzed. We also included sera from 11 patients with lymphocytic hypophysitis (3 biopsy-proven, 8 suspected), 17 with autoimmune Addison's disease, 20 with type 1 diabetes mellitus, 20 with Sjögren's syndrome, and 25 with systemic lupus erythematosus. Ninety healthy Swedish blood donors served as controls. All subjects gave their informed consent to the study, which was approved by the local ethical committees at Uppsala University and Karolinska Institutet. 
